Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia
Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 w...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1989-07, Vol.24 Suppl 1 (S1), p.S16-S19 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S19 |
|---|---|
| container_issue | S1 |
| container_start_page | S16 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 24 Suppl 1 |
| creator | Henze, G Fengler, R Hartmann, R Dopfer, R Göbel, U Graf, N Jürgens, H Niethammer, D Ritter, J Schellong, G |
| description | Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies. |
| doi_str_mv | 10.1007/BF00253232 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79123022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79123022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c197t-29c3861ede549afaebee7f2b267e6355df30c921959b8b9fd20b843717ad2e1c3</originalsourceid><addsrcrecordid>eNpFkEFLwzAYhoMoc04v3oWcPAjVL0nbLEcdToWhFz2XJP1Cq6mpSYvs31vZ0NN7eXjheQg5Z3DNAOTN3RqAF4ILfkDmLBc8g2UuDskcRJ5nhYT8mJyk9A4AORNiRma8LKVcyjl5XjXYhaHBqPstdSFSEz6RdjrG8E0jet0npMFR27S-bkKoqbbjgNRvu74Jxus0tJZ6HD-wa_UpOXLaJzzb74K8re9fV4_Z5uXhaXW7ySxTcsi4smJZMqyxyJV2Gg2idNzwUmIpiqJ2AqziTBXKLI1yNQczGUkmdc2RWbEgl7vfPoavEdNQdW2y6L3-xDCmSirGBXA-gVc70MaQUkRX9bGd7LYVg-o3XvUfb4Iv9q-j6bD-Q_e1xA9R9WoN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79123022</pqid></control><display><type>article</type><title>Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Henze, G ; Fengler, R ; Hartmann, R ; Dopfer, R ; Göbel, U ; Graf, N ; Jürgens, H ; Niethammer, D ; Ritter, J ; Schellong, G</creator><creatorcontrib>Henze, G ; Fengler, R ; Hartmann, R ; Dopfer, R ; Göbel, U ; Graf, N ; Jürgens, H ; Niethammer, D ; Ritter, J ; Schellong, G</creatorcontrib><description>Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00253232</identifier><identifier>PMID: 2667787</identifier><language>eng</language><publisher>Germany</publisher><subject>Adolescent ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Marrow Diseases - drug therapy ; Bone Marrow Diseases - mortality ; Bone Marrow Transplantation ; Child ; Combined Modality Therapy ; Humans ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality ; Random Allocation ; Recurrence ; Remission Induction ; Time Factors</subject><ispartof>Cancer chemotherapy and pharmacology, 1989-07, Vol.24 Suppl 1 (S1), p.S16-S19</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c197t-29c3861ede549afaebee7f2b267e6355df30c921959b8b9fd20b843717ad2e1c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2667787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henze, G</creatorcontrib><creatorcontrib>Fengler, R</creatorcontrib><creatorcontrib>Hartmann, R</creatorcontrib><creatorcontrib>Dopfer, R</creatorcontrib><creatorcontrib>Göbel, U</creatorcontrib><creatorcontrib>Graf, N</creatorcontrib><creatorcontrib>Jürgens, H</creatorcontrib><creatorcontrib>Niethammer, D</creatorcontrib><creatorcontrib>Ritter, J</creatorcontrib><creatorcontrib>Schellong, G</creatorcontrib><title>Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.</description><subject>Adolescent</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone Marrow Diseases - drug therapy</subject><subject>Bone Marrow Diseases - mortality</subject><subject>Bone Marrow Transplantation</subject><subject>Child</subject><subject>Combined Modality Therapy</subject><subject>Humans</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</subject><subject>Random Allocation</subject><subject>Recurrence</subject><subject>Remission Induction</subject><subject>Time Factors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEFLwzAYhoMoc04v3oWcPAjVL0nbLEcdToWhFz2XJP1Cq6mpSYvs31vZ0NN7eXjheQg5Z3DNAOTN3RqAF4ILfkDmLBc8g2UuDskcRJ5nhYT8mJyk9A4AORNiRma8LKVcyjl5XjXYhaHBqPstdSFSEz6RdjrG8E0jet0npMFR27S-bkKoqbbjgNRvu74Jxus0tJZ6HD-wa_UpOXLaJzzb74K8re9fV4_Z5uXhaXW7ySxTcsi4smJZMqyxyJV2Gg2idNzwUmIpiqJ2AqziTBXKLI1yNQczGUkmdc2RWbEgl7vfPoavEdNQdW2y6L3-xDCmSirGBXA-gVc70MaQUkRX9bGd7LYVg-o3XvUfb4Iv9q-j6bD-Q_e1xA9R9WoN</recordid><startdate>198907</startdate><enddate>198907</enddate><creator>Henze, G</creator><creator>Fengler, R</creator><creator>Hartmann, R</creator><creator>Dopfer, R</creator><creator>Göbel, U</creator><creator>Graf, N</creator><creator>Jürgens, H</creator><creator>Niethammer, D</creator><creator>Ritter, J</creator><creator>Schellong, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198907</creationdate><title>Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia</title><author>Henze, G ; Fengler, R ; Hartmann, R ; Dopfer, R ; Göbel, U ; Graf, N ; Jürgens, H ; Niethammer, D ; Ritter, J ; Schellong, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c197t-29c3861ede549afaebee7f2b267e6355df30c921959b8b9fd20b843717ad2e1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adolescent</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone Marrow Diseases - drug therapy</topic><topic>Bone Marrow Diseases - mortality</topic><topic>Bone Marrow Transplantation</topic><topic>Child</topic><topic>Combined Modality Therapy</topic><topic>Humans</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</topic><topic>Random Allocation</topic><topic>Recurrence</topic><topic>Remission Induction</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henze, G</creatorcontrib><creatorcontrib>Fengler, R</creatorcontrib><creatorcontrib>Hartmann, R</creatorcontrib><creatorcontrib>Dopfer, R</creatorcontrib><creatorcontrib>Göbel, U</creatorcontrib><creatorcontrib>Graf, N</creatorcontrib><creatorcontrib>Jürgens, H</creatorcontrib><creatorcontrib>Niethammer, D</creatorcontrib><creatorcontrib>Ritter, J</creatorcontrib><creatorcontrib>Schellong, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henze, G</au><au>Fengler, R</au><au>Hartmann, R</au><au>Dopfer, R</au><au>Göbel, U</au><au>Graf, N</au><au>Jürgens, H</au><au>Niethammer, D</au><au>Ritter, J</au><au>Schellong, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1989-07</date><risdate>1989</risdate><volume>24 Suppl 1</volume><issue>S1</issue><spage>S16</spage><epage>S19</epage><pages>S16-S19</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.</abstract><cop>Germany</cop><pmid>2667787</pmid><doi>10.1007/BF00253232</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1989-07, Vol.24 Suppl 1 (S1), p.S16-S19 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79123022 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Marrow Diseases - drug therapy Bone Marrow Diseases - mortality Bone Marrow Transplantation Child Combined Modality Therapy Humans Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Random Allocation Recurrence Remission Induction Time Factors |
| title | Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A07%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemotherapy%20for%20bone%20marrow%20relapse%20of%20childhood%20acute%20lymphoblastic%20leukemia&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Henze,%20G&rft.date=1989-07&rft.volume=24%20Suppl%201&rft.issue=S1&rft.spage=S16&rft.epage=S19&rft.pages=S16-S19&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/BF00253232&rft_dat=%3Cproquest_cross%3E79123022%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79123022&rft_id=info:pmid/2667787&rfr_iscdi=true |